Prognostic effect of serum BDNF levels in late-life depression: Moderated by childhood trauma and SSRI usage?

Dimitriadis, Menelaos; Brink, Rob H. S. van den; Comijs, Hannie C.; Voshaar, Richard C. Oude

doi:10.1016/j.psyneuen.2019.02.003

Cited by 12 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brain-derived neurotrophic factors (BDNF) can reverse defects in synaptic plasticity caused by stress, thereby enhancing flexibility against depression. BDNF levels in patients with LLD are significantly lower than those in healthy individuals (57,58). And when compared to a control group, DNA methylation of BDNF in the LLD group was significantly higher (59).…”

Section: The Multiple Pathogenesis Of Lldmentioning

confidence: 77%

Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic

Zhao

Tang³

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

Late-life depression (LLD) is one of the most common mental disorders among the older adults. Population aging, social stress, and the COVID-19 pandemic have significantly affected the emotional health of older adults, resulting in a worldwide prevalence of LLD. The clinical phenotypes between LLD and adult depression differ in terms of symptoms, comorbid physical diseases, and coexisting cognitive impairments. Many pathological factors such as the imbalance of neurotransmitters, a decrease in neurotrophic factors, an increase in β-amyloid production, dysregulation of the hypothalamic-pituitary-adrenal axis, and changes in the gut microbiota, are allegedly associated with the onset of LLD. However, the exact pathogenic mechanism underlying LLD remains unclear. Traditional selective serotonin reuptake inhibitor therapy results in poor responsiveness and side effects during LLD treatment. Neuromodulation therapies and complementary and integrative therapies have been proven safe and effective for the treatment of LLD. Importantly, during the COVID-19 pandemic, modern digital health intervention technologies, including socially assistive robots and app-based interventions, have proven to be advantageous in providing personal services to patients with LLD.

show abstract

Section: The Multiple Pathogenesis Of Lldmentioning

confidence: 77%

Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic

Zhao

Tang³

et al. 2023

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…In this study, BDNF concentrations were not different between depressed older adults and controls. Most interestingly, one recent study found that the impact of BDNF serum levels on the course of late-life depression was conditional on the presence of both the use of SSRIs and a history of childhood trauma (Dimitriadis et al, 2019). Based on these results, the authors hypothesized that childhood trauma may permanently reduce ("blunt") the responsiveness of the neurotrophic system to SSRI usage and that this responsiveness might be more important for depression course than the actual BDNF serum levels (Dimitriadis et al, 2019).…”

Section: Aging Depression and Bdnfmentioning

confidence: 99%

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Arosio

Guerini

Voshaar

et al. 2021

Front. Behav. Neurosci.

View full text Add to dashboard Cite

Major depressive disorder (MDD) affects millions of people worldwide and is a leading cause of disability. Several theories have been proposed to explain its pathological mechanisms, and the “neurotrophin hypothesis of depression” involves one of the most relevant pathways. Brain-derived neurotrophic factor (BDNF) is an important neurotrophin, and it has been extensively investigated in both experimental models and clinical studies of MDD. Robust empirical findings have indicated an association between increased BDNF gene expression and peripheral concentration with improved neuronal plasticity and neurogenesis. Additionally, several studies have indicated the blunt expression of BDNF in carriers of the Val66Met gene polymorphism and lower blood BDNF (serum or plasma) levels in depressed individuals. Clinical trials have yielded mixed results with different treatment options, peripheral blood BDNF measurement techniques, and time of observation. Previous meta-analyses of MDD treatment have indicated that antidepressants and electroconvulsive therapy showed higher levels of blood BDNF after treatment but not with physical exercise, psychotherapy, or direct current stimulation. Moreover, the rapid-acting antidepressant ketamine has presented an early increase in blood BDNF concentration. Although evidence has pointed to increased levels of BDNF after antidepressant therapy, several factors, such as heterogeneous results, low sample size, publication bias, and different BDNF measurements (serum or plasma), pose a challenge in the interpretation of the relation between peripheral blood BDNF and MDD. These potential gaps in the literature have not been properly addressed in previous narrative reviews. In this review, current evidence regarding BDNF function, genetics and epigenetics, expression, and results from clinical trials is summarized, putting the literature into a translational perspective on MDD. In general, blood BDNF cannot be recommended for use as a biomarker in clinical practice. Moreover, future studies should expand the evidence with larger samples, use the serum or serum: whole blood concentration of BDNF as a more accurate measure of peripheral BDNF, and compare its change upon different treatment modalities of MDD.

show abstract

“…Again, a high baseline BDNF level was associated to a positive response to ADs [182]. For these reasons, peripheral BDNF was proposed as a potential diagnostic, prognostic, and therapeutic biomarker for mood disorders, particularly associated with disease severity and response to AD treatments [181][182][183]. However, results are still inconclusive [184][185][186], as high blood BDNF levels were revealed also in resistant depression subjects under pharmacological treatment [44].…”

Section: Bdnf and Inflammatory Responses In Mood Disordersmentioning

confidence: 99%

State-of-the-Art: Inflammatory and Metabolic Markers in Mood Disorders

Mucci

Marazziti

Vecchia

et al. 2020

Life

View full text Add to dashboard Cite

Mounting evidence highlights the involvement of inflammatory/immune systems and their relationships with neurotransmitters and different metabolic processes in mood disorders. Nevertheless, there is a general agreement that available findings are still inconclusive. Therefore, further investigations are required, aimed at deepening the role of possible alterations of biomarkers in the pathophysiology of mood disorders that might lead to more focused and tailored treatments. The present study is a comprehensive review on these topics that seem to represent intriguing avenues for the development of real innovative therapeutic strategies of mood disorders.

show abstract

Prognostic effect of serum BDNF levels in late-life depression: Moderated by childhood trauma and SSRI usage?

Cited by 12 publications

References 53 publications

Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic

Late-life depression: Epidemiology, phenotype, pathogenesis and treatment before and during the COVID-19 pandemic

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

State-of-the-Art: Inflammatory and Metabolic Markers in Mood Disorders

Contact Info

Product

Resources

About